Independent committee approves second dose cohort for AMT-191 trial in Fabry disease, enrollment expected to begin Q1 2025.
Quiver AI Summary
uniQure N.V. announced the completion of enrollment for the first cohort of its Phase I/IIa trial for AMT-191, a gene therapy aimed at treating Fabry disease. The Independent Data Monitoring Committee reviewed initial safety data from the first two patients and found no significant safety concerns, recommending that enrollment of the second cohort proceed, expected to begin in Q1 2025. Chief Medical Officer Walid Abi-Saab expressed optimism about AMT-191's early results, which includes encouraging pharmacodynamics and safety profiles. AMT-191 aims to address the unmet medical needs of Fabry disease patients, offering a potential new treatment option through a single intravenous administration targeting the liver. The trial will monitor safety, tolerability, and early efficacy over a 24-month period.
Potential Positives
- Independent Data Monitoring Committee's recommendation to proceed with dosing of the second cohort indicates strong safety data from initial patients, which may bolster confidence in AMT-191's development.
- Completion of enrollment for the first cohort marks a significant milestone in the Phase I/IIa trial of AMT-191 for Fabry disease, advancing the company's clinical program.
- uniQure expects to initiate enrollment of the second dose cohort in the first quarter of 2025, demonstrating progress and commitment to the trial timeline.
- AMT-191 being designated as an investigational gene therapy offers a potentially novel treatment option for patients with Fabry disease, addressing a significant unmet medical need.
Potential Negatives
- Announcement of the second cohort enrollment is set for a significant time in the future (first quarter of 2025), indicating potential delays in the clinical development timeline for AMT-191.
- The press release emphasizes "significant unmet medical need," highlighting the urgency of the situation, which could draw attention to the company's previous delays or insufficient progress in addressing Fabry disease.
- Use of terms like "forward-looking statements" introduces uncertainty about the future success of AMT-191 and other programs, indicating that results may not materialize as anticipated.
FAQ
What is AMT-191?
AMT-191 is an investigational gene therapy aimed at treating Fabry disease by delivering a GLA transgene to the liver.
When will the second dose cohort of AMT-191 be enrolled?
Enrollment for the second dose cohort is expected to begin in the first quarter of 2025.
What does the IDMC recommend regarding AMT-191?
The Independent Data Monitoring Committee recommended proceeding with the dosing of the second cohort after reviewing safety data.
Why is there a need for AMT-191?
Fabry disease represents a significant unmet medical need, with current treatments proving limited in effectiveness for many patients.
What is the treatment method for AMT-191?
AMT-191 is administered through a one-time intravenous infusion, utilizing AAV5-based gene therapy technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$QURE Insider Trading Activity
$QURE insiders have traded $QURE stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $QURE stock by insiders over the last 6 months:
- MATTHEW C KAPUSTA (CEO, Managing Director) has made 0 purchases and 2 sales selling 103,418 shares for an estimated $1,529,079.
- CHRISTIAN KLEMT (Chief Financial Officer) sold 1,796 shares for an estimated $13,559
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$QURE Hedge Fund Activity
We have seen 63 institutional investors add shares of $QURE stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BOXER CAPITAL, LLC added 2,225,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $10,969,250
- MILLENNIUM MANAGEMENT LLC added 1,674,760 shares (+325.1%) to their portfolio in Q3 2024, for an estimated $8,256,566
- FRANKLIN RESOURCES INC added 1,492,962 shares (+inf%) to their portfolio in Q3 2024, for an estimated $7,360,302
- ADAR1 CAPITAL MANAGEMENT, LLC removed 1,222,676 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $6,027,792
- MARSHALL WACE, LLP added 1,086,578 shares (+2780.5%) to their portfolio in Q3 2024, for an estimated $5,356,829
- POINT72 ASSET MANAGEMENT, L.P. added 752,889 shares (+336.1%) to their portfolio in Q3 2024, for an estimated $3,711,742
- CITADEL ADVISORS LLC removed 692,548 shares (-85.6%) from their portfolio in Q3 2024, for an estimated $3,414,261
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~
~ Company expects to initiate enrollment of second dose cohort in the first quarter of 2025 ~
LEXINGTON, Mass. and AMSTERDAM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of enrollment in the first cohort of the Phase I/IIa trial of AMT-191, an investigational gene therapy for the treatment of Fabry disease. Additionally, the Independent Data Monitoring Committee (IDMC) reviewed safety data from the initial two patients enrolled in the first cohort. The IDMC’s review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort.
“Fabry is a debilitating disease that continues to represent a significant unmet medical need,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure . “We are encouraged by the initial pharmacodynamics, biomarkers and safety profile observed to date for AMT-191 as well as the positive outcome of the IDMC review. This strengthens our confidence in the potential of AMT-191 to make a meaningful difference in the lives of patients with Fabry disease. We look forward to advancing to the second cohort in this important clinical program.”
AMT-191 is an investigational AAV5-based gene therapy that uses a proprietary, highly potent promoter to deliver a galactosidase alpha (GLA) transgene designed to target the liver to produce GLA protein. In patients with Fabry disease, a pathogenic variant in the GLA gene leads to α-galactosidase A (aGAL-A) enzyme deficiency, which in turn results in a progressive accumulation of lipids in multiple cell types, including kidney and heart cells, eventually resulting in a multi-system disorder. AMT-191 may offer a novel one-time intravenously administered approach to treating Fabry disease.
About the Phase I/IIa Clinical Program of AMT-191
The Phase I/IIa clinical trial of AMT-191 is a multi-center, open-label trial being conducted in the United States consisting of two dosing cohorts of up to six adult male patients each receiving an intravenous infusion of AMT-191. Patients will continue to receive their regular enzyme replacement therapy until the criteria for withdrawal is met and will be followed for a period of 24 months. The trial will explore the safety, tolerability, and early signs of efficacy by measuring the expression of lysosomal enzyme aGLA-A. Additional details are available on www.clinicaltrials.gov (NCT06270316).
AMT-162 has been granted both Orphan Drug status and Fast Track designation by the U.S. Food and Drug Administration.
About Fabry Disease
Fabry disease is an X-linked genetic disorder resulting from a deficiency of GLA. Based on a 2020 study published in the Journal of Therapeutics and Clinical Risk Management, the prevalence is estimated to be between one in 40,000 and one in 117,000 individuals. The current standard of care for Fabry disease is bi-weekly infusions of enzyme replacement therapy, a treatment with limited effectiveness in many patients due to poor cross-correction, with inefficient clearance of substrates in the target organs, in particular the kidney and the heart.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements regarding the Company’s plans to initiate enrollment of the second dose cohort of the AMT-191 study in the first quarter of 2025; the potential of AMT-191 to make a meaningful difference in the lives of patients and as a novel one-time intravenously administered approach to treating Fabry disease. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, without limitation, risks associated with the clinical results and the development and timing of the Company’s programs; the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to approval; risks associated with the implementation of the Company’s restructuring; the Company’s ability to continue to build and maintain the company infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of gene therapies; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the Company’s ability to obtain, maintain and protect intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC”), including its Annual Report on Form 10-K filed February 28, 2024, its Quarterly Report on Form 10-Q filed November 5, 2024, and in other filings that the Company makes with the SEC from time to time . Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
uniQure Contacts: | ||
FOR INVESTORS: | FOR MEDIA: | |
Chiara Russo
Direct: 617-306-9137 Mobile: 617-306-9137 [email protected] |
Tom Malone
Direct: 339-970-7558 Mobile:339-223-8541 [email protected] |